 |
|
Advances in screening and markers improve early detection of colorectal cancer
May 23, 2007Although colorectal cancer is the second leading cause of cancer death in the United States, when detected early, it has one of the highest cure rates. For this reason, innovative and improved methods to screen for and detect this disease are essential. Research presented today at Digestive Disease Week® 2007 (DDW®) demonstrates the breadth of technological and research advances that are helping to decrease both the number of deaths and the number of new cases of colorectal cancer diagnosed in the United States. DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
A New Benchmark in the Colorectal Neoplasm Miss Rate During Colonoscopy: Results of a Randomized Controlled Trial of Wide Angle View (170 degrees) Colonoscopy Comparing Narrow Band Imaging and White Light (Abstract #821)
Although the colonoscopy is considered the most effective means to detect precursors of colon cancer, the overall reported rate of missing colorectal tumors is 24 percent, as reported in 1997. In the past 10 years, significant advances in screening technologies have led to the development of colonoscopes (long, flexible, lighted tubes with attached cameras) that have a wider angle of view and non-white light capabilities, such as narrow band imaging (NBI). Researchers from the Veterans Affairs Palo Alto Medical Center in Palo Alto, Calif. utilized current technologies to study the colonoscopic polyp miss rate, comparing NBI to white light imaging.
NBI changes the white light normally emitted by the colonoscope to a bluish light, providing a narrower wavelength and enhancing visual contrast of the surface structure of the colon. In this study, two consecutive, same-day colonoscopies were performed in 276 patients. All colonoscopies used a wide angle of view (170 degrees compared to standard 140) and high resolution capabilities. The patients were randomly assigned to white light (141 patients) or NBI (135 patients) during the first withdrawal, and then immediately underwent a second examination by the same physician using white light.
The study found an overall miss rate of 12 percent for tumors of any size and three percent for tumors greater than or equal to six millimeters. No lesion larger than one centimeter was missed and all missed tumors were tubular adenomas, or non-cancerous tumors. Based on these results, researchers established the colorectal tumor miss rate as zero percent (up to 2%) for significant tumors and 12 percent for all tumors. However, no significant difference of missed lesions was found between NBI and white light.
"Our findings suggest that technological advances have led to a significant reduction in the overall colorectal tumor miss rate, establishing a new benchmark for more accurate screening and detection," said Roy Soetikno, M.D., of Stanford University in Stanford, Calif., and senior author of the study. "Our study reaffirms the role of colonoscopy as the gold standard method to screen for colorectal cancer."
Dr. Soetikno will present this study on Wednesday, May 23, at 8:35 a.m. in Ball Room AB.
The Association of Elevated C-Reactive Protein Levels with Synchronous and Advanced Colorectal Adenoma (Abstract #S1987)
Inflammation has been implicated in numerous diseases through recent research. High levels of C-reactive protein (CRP) - a protein found in the blood that can be used to detect or grade inflammation - are often associated with cardiovascular disease and cancers, such as colorectal cancer. Little is known, however, about CRP levels and non-cancerous colorectal tumors (adenomas) that precede colorectal cancer. Researchers from National Taiwan University Hospital in Taipei, Taiwan, examined levels of CRP in both men and women, finding that elevated levels may be associated with increased risk of colorectal adenoma, but only in men.
Study authors conducted a cross-sectional study of plasma CRP levels in 6,695 Chinese patients. All patients underwent a complete total colonoscopy and thorough health check-up. Results were adjusted for age, gender, history of colon polyp, diabetes, hypertension, hypertriglyceridemia, hypercholesterolemia, physical activity, alcohol intake, smoking, white blood cell counts and abdominal obesity.
Results demonstrated that plasma CRP levels were significantly higher in patients in whom colorectal tumors were forming when compared to patients without tumor development. The presence of tumors forming at the same time, known as synchronous neoplasia, and advanced tumor development were associated with elevated levels of plasma CRP. However, while researchers found that high CRP levels are associated with the risk of colorectal tumor formation in male patients, the study did not find a corresponding association with female patients.
"These findings support the crucial role of chronic inflammation in the development of colorectal cancer," said Han-Mo Chiu, M.D., of the National Taiwan University Hospital, and senior author of this study. "These data warrant further investigations that will continue to evaluate C-reactive protein levels as an indicator of colorectal cancer and examine the gender differences found in our study."
Dr. Chiu will present this study on Sunday, May 20, at 8:00 a.m. in Hall E.
American Gastroenterological Association
NBI changes the white light normally emitted by the colonoscope to a bluish light, providing a narrower wavelength and enhancing visual contrast of the surface structure of the colon. In this study, two consecutive, same-day colonoscopies were performed in 276 patients. All colonoscopies used a wide angle of view (170 degrees compared to standard 140) and high resolution capabilities. The patients were randomly assigned to white light (141 patients) or NBI (135 patients) during the first withdrawal, and then immediately underwent a second examination by the same physician using white light.
The study found an overall miss rate of 12 percent for tumors of any size and three percent for tumors greater than or equal to six millimeters. No lesion larger than one centimeter was missed and all missed tumors were tubular adenomas, or non-cancerous tumors. Based on these results, researchers established the colorectal tumor miss rate as zero percent (up to 2%) for significant tumors and 12 percent for all tumors. However, no significant difference of missed lesions was found between NBI and white light.
"Our findings suggest that technological advances have led to a significant reduction in the overall colorectal tumor miss rate, establishing a new benchmark for more accurate screening and detection," said Roy Soetikno, M.D., of Stanford University in Stanford, Calif., and senior author of the study. "Our study reaffirms the role of colonoscopy as the gold standard method to screen for colorectal cancer."
Dr. Soetikno will present this study on Wednesday, May 23, at 8:35 a.m. in Ball Room AB.
The Association of Elevated C-Reactive Protein Levels with Synchronous and Advanced Colorectal Adenoma (Abstract #S1987)
Inflammation has been implicated in numerous diseases through recent research. High levels of C-reactive protein (CRP) - a protein found in the blood that can be used to detect or grade inflammation - are often associated with cardiovascular disease and cancers, such as colorectal cancer. Little is known, however, about CRP levels and non-cancerous colorectal tumors (adenomas) that precede colorectal cancer. Researchers from National Taiwan University Hospital in Taipei, Taiwan, examined levels of CRP in both men and women, finding that elevated levels may be associated with increased risk of colorectal adenoma, but only in men.
Study authors conducted a cross-sectional study of plasma CRP levels in 6,695 Chinese patients. All patients underwent a complete total colonoscopy and thorough health check-up. Results were adjusted for age, gender, history of colon polyp, diabetes, hypertension, hypertriglyceridemia, hypercholesterolemia, physical activity, alcohol intake, smoking, white blood cell counts and abdominal obesity.
Results demonstrated that plasma CRP levels were significantly higher in patients in whom colorectal tumors were forming when compared to patients without tumor development. The presence of tumors forming at the same time, known as synchronous neoplasia, and advanced tumor development were associated with elevated levels of plasma CRP. However, while researchers found that high CRP levels are associated with the risk of colorectal tumor formation in male patients, the study did not find a corresponding association with female patients.
"These findings support the crucial role of chronic inflammation in the development of colorectal cancer," said Han-Mo Chiu, M.D., of the National Taiwan University Hospital, and senior author of this study. "These data warrant further investigations that will continue to evaluate C-reactive protein levels as an indicator of colorectal cancer and examine the gender differences found in our study."
Dr. Chiu will present this study on Sunday, May 20, at 8:00 a.m. in Hall E.
American Gastroenterological Association
Colorectal Cancer Current Events and Colorectal Cancer News RSS'Cross-talk' mechanism contributes to colorectal cancer
Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.
African-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
Colon cancer screening more effective earlier in day, UCLA study finds
The effectiveness of a screening colonoscopy may depend on the time of day it is performed. According to a new UCLA study, early-morning colonoscopies yielded more polyps per patient than later screenings, and fewer polyps were found hour by hour as the day progressed.
1 disease, not 1 demographic
The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."
Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients
Researchers from Taiwan report in a new study that unsedated colonoscopy for primary colorectal cancer screening is well accepted in a majority of patients.
M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers
Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.
The bowels of infection
Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.
How to Lower Costs, Waiting Times for Colonoscopies
Colorectal cancer is a leading cause of cancer-related deaths in the United States, leading to over 50,000 fatalities every year.
Excess body weight causes over 124,000 new cancers a year in Europe
At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study.
Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent
Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage.
More Colorectal Cancer Current Events and Colorectal Cancer News Articles
 |
American Cancer Society's Complete Guide to Colorectal Cancer by American Cancer Society (Author) Don't die of embarrassment--get informed about colorectal cancer Although colorectal cancer is the third most common cancer found in men and women, you may be unaware of your risk and don't know what you can do to prevent this serious disease. You may be too embarrassed to ask your doctor about changes in your bowel habits or get screened for colorectal cancer. American Cancer Society's Complete Guide to Colorectal Cancer provides sound information and support if you are concerned about or diagnosed with colorectal cancer. Written by experts in oncology, nursing, research, and colorectal cancer care, the up-to-date, evidence-based text explores every aspect of colorectal cancer, from physical to emotional aspects of the disease, including: What colorectal... |
 |
Be a Survivor: Colorectal Cancer Treatment Guide by Vladimir Lange (Author) Dr. Lange’s comprehensive overview of cancer and treatment options offers detailed information using simple, concise language and a wide variety of color photos and drawings. Colorectal cancer patients need to know more about their disease, yet there is an overload of information. Be a Survivor gives the patient the specific, reliable and necessary information to make good decisions about their cancer and treatment options. Annually, 150,000 Americans are told they have colorectal cancer, making it one of the top three most common cancers in the United States. Diagnosed early, colorectal cancer is treatable, often curable, and vey preventable. This resource covers all aspects of colorectal cancer—from diagnosis to recovery, including a chapter for the patient's spouse. |
|
Progress in Colorectal Cancer by Mediscript | |
 |
First Check Home ColoCheck Home Test, Colorectal Disease, 1 Test (Pack of 2) by First Check A First Check at 50 product. No specimen handling. No diet restrictions. FDA cleared. Fast. Accurate. Simple. A home test for the early warning signs of Colorectal Disease. Results in minutes. Early detection is key. First Check ColoCheck provides informa |
 |
New Tests, Treatments: Better Outcome for Colorectal Cancer Colorectal cancer is the third most common cancer and the second leading cause of cancer mortality in the U.S. Advances in imaging, genetics, molecular diagnostics, surgical techniques and chemotherapy are now making significant gains in our ability to prevent, diagnose, and treat this serious disease. Dr. Fisher reviews some of these recent successes and shares a vision of future care based on current research. |
|
Screening for Colorectal Cancer: An Easy Step to Save Your Life (Three Real Patient Stories) Also With: American Digestive Health Foundation (Producer), Chuck Peet (Host) | |
 |
Beating Colorectal Cancer Together Long Sleeve T-shirt Large White by Shop Zeus |
 |
Colorectal Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Colorectal Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Colorectal Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Colorectal Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Understanding Colorectal Cancer Anatomical Chart (Laminated) by Anatomical Chart Company Understanding Colorectal Cancer Anatomical Chart defines colorectal cancer and shows colorectal anatomy with the following pathologies: * Adenocarcinoma of colon * Circumferential carcinoma of the transverse colon * Colonic polyps * Adenocarcinoma of jejunum * Adenocarcinoma of the rectosigmoid region The chart describes risk factors, signs and symptoms, screening and diagnostic tests, and treatment options, and illustrates and explains the stages of cancer. |
 |
Beating Colorectal Cancer Together Keychain by Design a Product LLC Text on keychain: Beating Colorectal Cancer Together * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
| © 2009 BrightSurf.com |